Vixeos combination for intravenous injection (Daunorubicin hydrochloride・Cytarabine), from Nippon Shinyaku (YJ code: 4291502D1029, standard: (144mg) x 1 bottle), treats newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes. This liposomal chemotherapy combines daunorubicin and cytarabine to inhibit cancer cell growth.
Vixeos combination for intravenous injection
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).